menu
    • menu

    Company profile for Ionctura

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ionctura’s pipeline contains an exquisitely selective PI3Kδ small molecule inhibitor which has just entered a phase I clinical trial in solid tumours, a second generation selective ATX small molecule inhibitor that is in IND enabling studies and an early preclinical phase anti-CD73 antibody program. Developing molecules that individually harness the combined effect of immune-mediated and direct anti-tumour activity.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    IoncturaSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Campus Biotech Innovation Park, Bâtiment F2, Avenue Sécheron 15, Geneva
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ionctura.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ionctura
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ionctura Presents (IOA-289) Clinical Data For Pancreatic Cancer
    Ionctura Presents (IOA-289) Clinical Data For Pancreatic Cancer

    14 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ionctura-debuts-cambritaxestat-ioa-28g-clinical-data-in-patients-with-pancreatic-cancer-at-esmo-302583167.html

    PR NEWSWIRE
    14 Oct 2025
    Share Share
    iOnctura Advances Roginolisib Trials in US, Expands Oncology
    iOnctura Advances Roginolisib Trials in US, Expands Oncology

    09 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ionctura-expands-roginolisib-trials-to-the-us-advancing-multi-indication-strategy-in-oncology-302549542.html

    PR NEWSWIRE
    09 Sep 2025
    Share Share
    iOnctura Bolsters Expertise with Two Board Appointments
    iOnctura Bolsters Expertise with Two Board Appointments

    24 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ionctura-strengthens-medical-and-commercialization-expertise-with-two-non-executive-board-appointments-302512284.html

    PR NEWSWIRE
    24 Jul 2025
    Share Share
    iOnctura Bolsters Leadership Team with New Appointments
    iOnctura Bolsters Leadership Team with New Appointments

    02 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ionctura-bolsters-leadership-team-with-new-appointments-302469654.html

    PR NEWSWIRE
    02 Jun 2025
    Share Share
    iOnctura commences Phase I/II study in non-small cell lung cancer
    iOnctura commences Phase I/II study in non-small cell lung cancer

    08 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ionctura-commences-randomized-phase-iii-study-in-non-small-cell-lung-cancer-302449067.html

    PR NEWSWIRE
    08 May 2025
    Share Share
    iOnctura starts Phase II study in metastatic uveal melanoma
    iOnctura starts Phase II study in metastatic uveal melanoma

    20 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ionctura-commences-randomized-phase-ii-study-in-metastatic-uveal-melanoma-302406926.html

    PR NEWSWIRE
    20 Mar 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search